2.要約四半期連結財務諸表及び主な注記
(1)要約四半期連結財政状態計算書
| | (単位:千円) |
| 前連結会計年度 (2025年12月31日) | 当第1四半期連結会計期間 (2026年3月31日) |
資産 | | |
流動資産 | | |
現金及び現金同等物 | 1,918,615 | 1,787,964 |
売上債権 | 350 | 300 |
棚卸資産 | 3,759 | 5,341 |
その他の流動資産 | 46,271 | 59,962 |
流動資産合計 | 1,968,995 | 1,853,567 |
非流動資産 | | |
その他の非流動資産 | 10,462 | 10,442 |
非流動資産合計 | 10,462 | 10,442 |
資産合計 | 1,979,457 | 1,864,009 |
| | |
負債及び資本 | | |
負債 | | |
流動負債 | | |
買掛金 | 21,358 | 30,084 |
未払債務 | 105,631 | 120,240 |
未払報酬 | 13,642 | 16,131 |
リース負債 | 13,989 | 18,534 |
その他の流動負債 | 2,753 | 2,833 |
流動負債合計 | 157,373 | 187,822 |
非流動負債 | | |
リース負債 | 8,252 | 664 |
非流動負債合計 | 8,252 | 664 |
負債合計 | 165,625 | 188,486 |
資本 | | |
資本金 | 577,576 | 658,427 |
資本剰余金 | 28,418,035 | 28,510,727 |
利益剰余金 | △25,732,895 | △26,045,021 |
その他の資本の構成要素 | △1,448,884 | △1,448,610 |
親会社の所有者に帰属する持分合計 | 1,813,832 | 1,675,523 |
資本合計 | 1,813,832 | 1,675,523 |
負債及び資本合計 | 1,979,457 | 1,864,009 |
E3285445960窪田製薬ホールディングス株式会社Kubota Pharmaceutical Holdings Co., Ltd.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2026-01-012026-03-31Q12026-12-312025-01-012025-03-312025-12-311falsefalsefalse459602026-05-14459602026-03-31459602026-01-012026-03-31459602025-03-31459602025-01-012025-03-31459602025-12-31459602024-12-31459602025-03-31jpigp_cor:RetainedEarningsIFRSMember459602025-03-31jpigp_cor:CapitalSurplusIFRSMember459602025-03-31jpigp_cor:ShareCapitalIFRSMember459602025-01-012025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602025-01-012025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember459602025-01-012025-03-31jpigp_cor:RetainedEarningsIFRSMember459602025-01-012025-03-31jpigp_cor:CapitalSurplusIFRSMember459602025-01-012025-03-31jpigp_cor:ShareCapitalIFRSMember459602024-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459602024-12-31jpigp_cor:RetainedEarningsIFRSMember459602024-12-31jpigp_cor:CapitalSurplusIFRSMember459602024-12-31jpigp_cor:ShareCapitalIFRSMember459602026-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602026-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember459602026-03-31jpigp_cor:RetainedEarningsIFRSMember459602026-03-31jpigp_cor:CapitalSurplusIFRSMember459602026-03-31jpigp_cor:ShareCapitalIFRSMember459602026-01-012026-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602026-01-012026-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember459602026-01-012026-03-31jpigp_cor:RetainedEarningsIFRSMember459602026-01-012026-03-31jpigp_cor:CapitalSurplusIFRSMember459602026-01-012026-03-31jpigp_cor:ShareCapitalIFRSMember459602025-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602025-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459602025-12-31jpigp_cor:RetainedEarningsIFRSMember459602025-12-31jpigp_cor:CapitalSurplusIFRSMember459602025-12-31jpigp_cor:ShareCapitalIFRSMember459602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember459602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMemberiso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure